title: Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain.
abstract: This double-blind, placebo-controlled study evaluated the efficacy and safety of hydrocodone extended release (ER) developed with abuse-deterrence technology to provide sustained pain relief and limit effects of alcohol and tablet manipulation on drug release. Eligible patients with chronic moderate-to-severe low back or osteoarthritis pain were titrated to an analgesic dose of hydrocodone ER (15-90 mg) and randomized to placebo or hydrocodone ER every 12 hours. The primary efficacy measure was change from baseline to week 12 in weekly average pain intensity (API; 0=no pain, 10=worst pain imaginable). Secondary measures included percentage of patients with >33% and >50% increases from baseline in weekly API, change from baseline in weekly worst pain intensity, supplemental opioid usage, aberrant drug-use behaviors, and adverse events. Overall, 294 patients were randomized and received ≥1 dose of placebo (n=148) or hydrocodone ER (n=146). Weekly API did not differ significantly between hydrocodone ER and placebo at week 12 (P=0.134); although, in post hoc analyses, the change in weekly API was significantly lower with hydrocodone ER when excluding the lowest dose (15 mg; least squares mean, -0.20 vs 0.40; P=0.032). Significantly more patients had >33% and >50% increase in weekly API with placebo (P<0.05), and mean weekly worst pain intensity was significantly lower with hydrocodone ER at week 12 (P=0.026). Supplemental medication usage was higher with placebo (86%) than hydrocodone ER (79%). Incidence of aberrant drug-use behaviors was low, and adverse events were similar between groups. This study did not meet the primary endpoint, although results support the effectiveness of this hydrocodone ER formulation in managing chronic low back or osteoarthritis pain. Use of the hydrocodone ER 15-mg dose, a robust placebo response, and use of supplemental analgesics, particularly in the placebo group, may have limited detection of a statistically significant treatment effect, and additional research is needed to clarify these findings.
authors.affiliation: Gold Coast Research, LLC, Plantation, FL, USA.
authors.forename: Martin E
authors.initials: ME
authors.lastname: Hale
authors.affiliation: Teva Branded Pharmaceutical Products R & D, Inc., Frazer, PA, USA.
authors.forename: Charles
authors.initials: C
authors.lastname: Laudadio
authors.affiliation: Teva Branded Pharmaceutical Products R & D, Inc., Frazer, PA, USA.
authors.forename: Ronghua
authors.initials: R
authors.lastname: Yang
authors.affiliation: Teva Branded Pharmaceutical Products R & D, Inc., Frazer, PA, USA.
authors.forename: Arvind
authors.initials: A
authors.lastname: Narayana
authors.affiliation: Teva Branded Pharmaceutical Products R & D, Inc., Frazer, PA, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Malamut
keywords: aberrant behaviors; abuse deterrent; clinical trial; opioid analgesics; opioid diversion; opioid loss